• br Conclusions The present protocol for localizing or

  2024-07-11

  

  Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A

• Interestingly we found that co treatment with losartan preve

  2024-07-11

  

  Interestingly, we found that co-treatment with losartan prevented the increased participation of ROS from NADPH oxidase on the contractile response to Phe observed in Hg-treated rats. Moreover, losartan also prevented the reduction in the endothelial NO modulation of this response found in treated a

• In summary the CV and renal

  2024-07-11

  

  In summary, the CV and renal benefits of sacubitril/valsartan in HF patients are attributed to the increased levels of peptides that are degraded by neprilysin and the simultaneous inhibition of the effects of AT1 receptor by valsartan (Fig. 1). Physical and chemical properties Sacubitril/Valsar

• [Ala107]-MBP (104-118) Evidence shows that glial activation

  2024-07-11

  

  Evidence shows that glial activation increases the expression of cytokines and chemokines in Parkinson's disease, which precede the degeneration of the substance nigra (Halliday and Stevens, 2011, Tansey and Goldberg, 2010). The use of non-steroidal anti-inflammatory drugs (except aspirin) can preve

• In the search for more specific

  2024-07-10

  

  In the search for more specific inhibitors of uptake2, Iversen and Salt (1970) speculated that steroids may potentiate the actions of catecholamines on vascular smooth muscle by inhibiting uptake2-mediated catecholamine clearance of the transmitters. They went on to demonstrate that a variety of ste

• br Funding This work was supported by

  2024-07-10

  

  Funding This work was supported by Arena Pharmaceuticals, Inc, San Diego, CA, USA. Introduction 5-hydroxytryptamine 1B (5-HT1B) receptors are widely distributed in the central nervous system (CNS); they have various modulatory functions in drug reinforcement, appetitive behaviors, stress, moo

• br Acknowledgments This work was supported by the R D

  2024-07-10

  

  Acknowledgments This work was supported by the R&D Program of the Institutional Research Program of KRICT (SI1701-02), and by the Next generation carbon upcycling project of Ministry of Science and ICT. JSC is kindly grateful to the National Research Council of Science and Technology (NST) for fi

• br Methods br Results and discussion br Conclusions br

  2024-07-10

  

  Methods Results and discussion Conclusions Acknowledgements The authors thank Dr. Francois Alhenc-Gelas (then INSERM U367, Paris, France), who kindly provided the plasmid for truncated soluble recombinant human ACE – WTΔ, Dr. Elena Arablinskaya (Institute of Phtiziopulmonology, Moscow, R

• Small kinase inhibitors have been developed to

  2024-07-10

  

  Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha

• br ACL Regulation and Role

  2024-07-10

  

  ACL Regulation and Role in Lipid Metabolism ACL is a ubiquitous enzyme at the nexus of nutrient catabolism and synthesis of cholesterol and fatty acids. In mammals, it is highly expressed in lipogenic tissues including adipose, liver, and lactating mammary glands [9]. In the presence of ATP and C

• AP activation is known to upregulate downstream target

  2024-07-10

  

  AP-1 activation is known to upregulate downstream target genes including apramycin D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in

• br Acknowledgements We would like to

  2024-07-10

  

  Acknowledgements We would like to thank Dr. Thomas Blanpied, Sai Sachin Divakaruni, Dr. Helmut Kessels, Feline Lindhout, Dieudonnée van de Willige, and all members of the MacGillavry lab for discussions and critical reading of the manuscript. This work was supported by NWO (ALW-VENI 863.13.020, A

• APJ receptor expression is altered in

  2024-07-10

  

  APJ receptor expression is altered in various cardiovascular diseases, and both increases as well as decreases in APJ receptor expression have been reported. A decrease in mRNA and protein levels of APJ receptors was observed in patients with ischemic heart disease or idiopathic dilated cardiomyopat

• A phase I trial has recently

  2024-07-09

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• Moreover a multiple regression analysis using the

  2024-07-09

  

  Moreover, a multiple regression analysis using the 1-year MMSE score as a dependent variable was conducted. The result showed that serum Siponimod mg levels at admission did not affect the MMSE score 1 year later (β = 0.10, p = 0.639). Discussion In this study, serum Aβ42 levels were significant

15797 records 69/1054 page Previous Next First page 上5页 6667686970 下5页 Last page